Clinical risk factors for portopulmonary hypertension†

Steven M. Kawut(University of Pennsylvania), Michael B. Fallon(University of Arizona), Neil Kaplowitz(University of Southern California), Evelyn M. Horn(Cornell University), David B. Badesch(University of Colorado Denver), Steven Zacks(University of North Carolina at Chapel Hill), Raymond L. Benza(Allegheny General Hospital), Darren B. Taichman(University of Pennsylvania), Robert S. Brown(Columbia University Irving Medical Center), Kari E. Roberts(Tufts Medical Center), James F. Trotter(Baylor Scott & White Health), Michael J. Krowka(Mayo Clinic)
Hepatology
March 19, 2008
10.1002/hep.22275
Cited by 286

Related Papers

Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial
|The Lancet|2008|2k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Predicting Survival in Pulmonary Arterial Hypertension
|Circulation|2010|1.5k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k